Ralliant (NYSE:RAL) Releases FY 2026 Earnings Guidance

Ralliant (NYSE:RAL) updated its FY 2026 earnings guidance on Thursday. The company provided EPS guidance of 2.760-2.900 for the period, compared to the consensus EPS estimate of 2.650. The company issued revenue guidance of $2.3 billion-$2.3 billion, compared to the consensus revenue estimate of $2.2 billion. Ralliant also updated its Q3 2026 guidance to 0.720-0.780 EPS.

Ralliant Price Performance

Shares of RAL opened at $66.85 on Thursday. The company’s 50-day moving average is $66.98 and its 200-day moving average is $54.16. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.61 and a quick ratio of 1.05. The firm has a market capitalization of $7.48 billion and a PE ratio of -6.11. Ralliant has a fifty-two week low of $37.27 and a fifty-two week high of $75.41.

Ralliant (NYSE:RAL) last announced its quarterly earnings results on Thursday, July 30th. The company reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.63 by $0.05. The business had revenue of $567.80 million for the quarter. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. Equities analysts forecast that Ralliant will post 2.64 EPS for the current year.

Ralliant Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 23rd. Stockholders of record on Monday, June 8th were issued a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, June 8th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Ralliant’s dividend payout ratio (DPR) is currently -1.83%.

Wall Street Analyst Weigh In

RAL has been the topic of several recent research reports. Oppenheimer raised their target price on shares of Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, May 13th. Wall Street Zen downgraded Ralliant from a “buy” rating to a “hold” rating in a research report on Sunday. Royal Bank Of Canada raised their price objective on Ralliant from $64.00 to $71.00 and gave the stock a “sector perform” rating in a research note on Thursday, July 16th. TD Cowen lifted their price objective on Ralliant from $55.00 to $70.00 and gave the company a “buy” rating in a report on Wednesday, May 20th. Finally, BMO Capital Markets initiated coverage on Ralliant in a research report on Monday, July 20th. They set a “market perform” rating and a $78.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Ralliant has an average rating of “Moderate Buy” and a consensus price target of $73.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of RAL. UMB Bank n.a. grew its position in Ralliant by 49.6% in the fourth quarter. UMB Bank n.a. now owns 983 shares of the company’s stock valued at $50,000 after acquiring an additional 326 shares during the last quarter. Maryland State Retirement & Pension System lifted its holdings in shares of Ralliant by 1.5% in the fourth quarter. Maryland State Retirement & Pension System now owns 21,940 shares of the company’s stock worth $1,117,000 after acquiring an additional 329 shares during the last quarter. Xponance LLC lifted its holdings in shares of Ralliant by 9.2% in the fourth quarter. Xponance LLC now owns 6,025 shares of the company’s stock worth $307,000 after acquiring an additional 509 shares during the last quarter. Palisade Asset Management LLC acquired a new stake in shares of Ralliant in the 3rd quarter valued at approximately $26,000. Finally, BOKF NA acquired a new stake in shares of Ralliant in the 3rd quarter valued at approximately $29,000.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.